Blood glucose control and monitoring in the critically ill

van Hooijdonk, R.T.M.

Citation for published version (APA):
Chapter 3

Glycemic Variability is Complex – is Glucose Complexity Variable?

Roosmarijn T.M. van Hooijdonk, Ameen Abu-Hanna, Marcus J. Schultz

Critical Care 2012, 16:178
Abstract
Observational studies show an independent association between increased glycemic variability and higher mortality in critically ill patients. Minimization of glycemic variability is therefore suggested as a new target of glycemic control, which may require very frequent or almost continuous monitoring of glucose levels. Brunner and colleagues show the use of real-time subcutaneous continuous glucose monitoring does not decrease glycemic variability. Continuous glucose monitoring, however, may reveal changes in glucose complexity, which may be of interest since both increased and decreased glucose complexity is associated with higher mortality in the critically ill.
In the previous issue of *Critical Care* Brunner and colleagues report on the results of a *post-hoc* analysis [1] of two previously published randomized controlled trials evaluating real-time subcutaneous continuous glucose monitoring (CGM) in critically ill patients [2,3]. Their main findings are that glycemic control guided by real-time CGM does not significantly reduce glycemic variability (GV) and that both increased and decreased glucose complexity is significantly associated with ICU survival and with the presence of diabetes. There is an independent association between increased GV and higher mortality in ICU patients [4,5]. GV depends on endogenous factors (for example, severity of illness) but also on exogenous factors (for example, inappropriate glucose measurement intervals and improper insulin adjustments). Minimization of GV is suggested as a new target of glycemic control [6], which may require very frequent or almost continuous monitoring of glucose levels. However, a secondary analysis of the first two Leuven studies shows that strict glycemic control, which includes frequent monitoring of the blood glucose level, does not decrease GV [7]. The present study shows that strict glycemic control using almost continuous monitoring also does not decrease GV [1].

Therefore it is very difficult, if not impossible, to decrease GV. Are the nurses in Brunner and colleagues’ ICU already performing strict glycemic control so well that GV simply cannot be further decreased? Notably, the standard deviation – one of the measures of GV used by the present analysis – is already very low in the control group compared with values reported in previous studies. Nurses could also poorly or only sporadically respond to the real-time CGM results with alterations in insulin infusion, thereby losing any potential for real-time CGM to further decrease GV. We should also not forget that the present study uses subcutaneous glucose levels and not blood glucose levels for calculation of indicators of GV. Subcutaneous GV may simply not be the same as blood GV. Finally, we must keep in mind that the sample frequency *per se* may affect the calculation of indicators of GV. Indeed, indicators of GV may not only truly reflect GV, but may also depend on the number of measurements per time unit used for its calculation [8]. Brunner and colleagues actually confirm this dependency in their analysis of the impact of the method of glucose determination on indicators of GV [1].

Less well known is that loss of glucose complexity is also associated with higher mortality of critically ill patients. Complex biological systems are characterized by a highly complex output, and one of the first symptoms of disease is decomplexification [9,10]. Well-known examples include decreased intrauterine heart rate complexity with fetal stress, and decreased heart rate and temperature complexity with severe infection. Complexity, in contrast to variability, depends on endogenous factors, and not on exogenous factors. Interestingly, progressive loss of glucose complexity is found from health through the metabolic syndrome to type II diabetes [11-14]. The results of the present study are in line with those findings, at least to some extent. They also echo the results from a previous investigation showing that loss of glucose complexity is associated with higher mortality [15]. The finding that increased glucose complexity is also associated with higher mortality, however, is new. Therefore, next to hyperglycemia, hypoglycemia and GV, glucose complexity should be seen as one new domain of glycemia (Figure 1), although glucose complexity cannot be changed by titration of insulin.

As we speak, several CGM systems are being developed and clinically tested
in critically ill patients. These systems all have the potential to improve performance and safety of insulin titration in the ICU. They may also improve our insights into insulin resistance and help us to better understand the impact of GV on outcome. The present study not only shows that GV does not improve with the use of CGM per se, but also suggests that we need to develop better measures of GV, independent of the sample frequency. Finally, CGM systems allow us to determine and follow changes in glucose complexity. This allows one to inspect whether glucose complexity increases (from decreased complexity) or decreases (from increased complexity) in individual patients, and to determine whether these changes follow changes in insulin resistance over time. If this indeed is the case, then CGM could even help us in decisions to start or stop strict glycemic control in individual patients, thereby preventing side effects of insulin infusion.

![Figure 1. Schematic view of the four domains of blood glucose control.](image)

**Figure 1.** Schematic view of the four domains of blood glucose control. [1] hyperglycemia, [2] hypoglycemia, [3] glycemic variability, and [4] glucose complexity. CGM, continuous glucose monitoring

**Competing Interests**

R.T.M. van Hooijdonk has performed consulting work for Medtronic Inc., GlySyre Ltd, and has received research support from Medtronic Inc. and Optiscan Biomedical. M.J. Schultz has performed consulting work for Medtronic Inc., GlySyre Ltd, Roche Diagnostics, Edwards Life Sciences and Optiscan Biomedical, and has received research support from Medtronic Inc. and Optiscan Biomedical. A. Abu-Hanna declares that he has no competing interests.

**Authors’ Contributions**

Drafting and critical revision of the manuscript: R.T.M. van Hooijdonk, A. Abu-Hanna and M.J. Schultz
References


